Lives unaffected by cystic fibrosis


Back to the Drug Development Pipeline

Intravenous Gallium

Phase Two

Phase Two

Therapeutic Approach


Gallium is a molecule, nearly identical to iron, that disrupts iron-dependent biological processes and has been shown to kill antibiotic-resistant strains of Pseudomonas aeruginosa in laboratory research. Gallium has already been approved by the FDA for intravenous use in people and is now being studied for its safety and effectiveness in controlling P. aeruginosa in people with CF.


 A phase 2 to test the safety and effectiveness of IV gallium in controlling P. aeruginosa in people with CF has been completed. A phase 1 study to test safety and effectiveness in adults with CF who have nontuberculous mycobacteria (NTM) is currently underway.


This program is sponsored by the Cystic Fibrosis Foundation and is being conducted within Therapeutics Development Network.

Contact us about Intravenous Gallium >